Certolizumab effective in preventing adverse pregnancy outcomes in high-risk antiphospholipid syndrome. CZP given to 51 APS pts wks 8 to 28. 9 w/ primary APO (17.6%) (6 w/ pregnancy loss <10 wks) - significantly lower than historical controls. Median delivery 36.5 wks. Neonatal https://t.co/KfOOM7sEAt